Download pdf
Protein structure prediction based on deep learning: HER2 in complex with a covalent inhibitor
- 1 Western University
* Author to whom correspondence should be addressed.
Abstract
HER2 protein overexpression is associated with the malignant degree and poor prognosis of breast cancer. HER2 levels are elevated in 20% of breast tumors. Several covalent tyrosine kinase inhibitors have been found to reduce tumor cell survival and proliferation in vitro and inhibit downstream HER2 signaling. In the field of protein structure prediction, AlphaFold2, which achieved excellent results in CASP14, can periodically predict protein structures with atomic precision in the absence of similar protein structures. In this study, AlphaFold2 was used to predict the monomeric structure of the HER2 protein. This predicted structure was compared to the conformation of HER2 in complex with a covalent inhibitor, allowing for an examination of the conformational changes induced by the inhibitor. By combining the conformational changes of HER2 protein with the docking results of Protein-Ligand Interaction Profiler, other potential binding sites were identified, which could further reveal the mechanism of drug discovery.
Keywords
deep learning, HER2, protein–ligand complex, protein structure prediction
[1]. O’Connor C M, Adams J U and Fairman J E 2010 Essentials of Cell Biology (Cambridge, MA: NPG Education)
[2]. Branden C I and Tooze J 2012 Introduction to Protein Structure, second edition (Boca Raton, FL: Garland Science)
[3]. Al-Lazikani B, Jung J, Xiang Z and Honig B 2001 Protein structure prediction Curr. Opin. Chem. Biol. 5 51–6
[4]. Kryshtafovych A, Schwede T, Topf M, Fidelis K and Moult J 2021 Critical assessment of methods of protein structure prediction (casp)—round xiv Proteins 89 1607–17
[5]. Jumper J et al. 2021 Highly accurate protein structure prediction with alphafold Nature 596 583–9
[6]. Gao M, Nakajima An D, Parks J M and Skolnick J 2022 Af2complex predicts direct physical interactions in multimeric proteins with deep learning Nat. Commun. 13 1744
[7]. Linger R M, Keating A K, Earp H S and Graham D K 2008 TAM Receptor Tyrosine Kinases: Biologic Functions, Signaling, and Potential Therapeutic Targeting in Human Cancer Adv. Cancer Res. 100 35–83
[8]. Hynes N E and MacDonald G 2009 ErbB receptors and signaling pathways in cancer Curr. Opin. Cell Biol. 21 177–84
[9]. Graus-Porta D 1997 ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling EMBO J. 16 1647–55
[10]. Yarden Y 2001 Biology of her2 and its importance in breast cancer Oncology, suppl.S2 61 1–13
[11]. Wilding B et al. 2022 Discovery of potent and selective her2 inhibitors with efficacy against her2 exon 20 insertion-driven tumors, which preserve wild-type egfr signaling Nat. Cancer 3 pp. 821–36
[12]. Berman H M 2000 The protein data bank Nucleic Acids Res. 28 pp. 235–42
[13]. Bader G 2022 Her2 in complex with a covalent inhibitor wwPDB
[14]. Schrödinger, LLC 2015 The PyMOL molecular graphics system, version 1.8
[15]. Adasme M F, Linnemann K L, Bolz S N, Kaiser F, Salentin S, Haupt V, and Schroeder M 2021 Plip 2021: expanding the scope of the protein–ligand interaction profiler to dna and rna Nucleic Acids Res. 49 W530–4
Cite this article
Yao,W. (2024). Protein structure prediction based on deep learning: HER2 in complex with a covalent inhibitor. Advances in Engineering Innovation,6,13-20.
Data availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
Disclaimer/Publisher's Note
The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
About volume
Journal：Advances in Engineering Innovation
© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and
conditions of the Creative Commons Attribution (CC BY) license. Authors who
publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons
Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this
series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published
version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial
publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and
during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See
Open access policy for details).